How do pharma companies structure themselves between corporate ventures and licensing?

Edition

How do pharma companies structure themselves between corporate ventures and licensing?

Pharma companies’ open innovation strategies often revolve around outsourcing, collaboration, licensing and equity investment. What are the financial and strategic objectives for choosing venture capital investment versus licensing?

At what stage do pharmaceutical companies consider licensing? To what extent do CVCs serve the innovation strategy of their parent company? What are the expected risks and rewards of both strategies and how do they articulate with each other?

Scroll to Top
  • No products in the cart.